Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pacific EdgeASX:PEB 40 Cyclically Adjusted PS Ratio is 12.00 as of Jul. 15, 2026, which is 62% below its 10-year median of 31.54. GuruFocus rates ASX:PEB with a GF Score™ of 40/100 and a GF Value™ of A$0.05 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 136 Medical Diagnostics & Research companies, Pacific Edge ranks worse than 91.91% on this metric.
The historical rank and industry rank for Pacific Edge's Cyclically Adjusted PS Ratio or its related term are showing as below:
ASX:PEB'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.9 Med: 31.54 Max: 156
Current: 14.98
During the past 13 years, Pacific Edge's highest Cyclically Adjusted PS Ratio was 156.00. The lowest was 2.90. And the median was 31.54.
ASX:PEB's Cyclically Adjusted PS Ratio is ranked worse than 91.91% of 136
companies
in the Medical Diagnostics & Research industry
Industry Median: 2
vs ASX:PEB: 14.98
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Pacific Edge's adjusted revenue per share data of for the fiscal year that ended in Mar26 was A$0.010. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is A$0.02 for the trailing ten years ended in Mar26.
Shiller PE for Stocks: The True Measure of Stock Valuation
Pacific Edge (ASX:PEB) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Pacific Edge Cyclically Adjusted PS Ratio Related Terms
Pacific Edge Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Pacific Edge's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:PEB vs TMO, DHR, IDXX: Cyclically Adjusted PS Ratio Comparison
For the Diagnostics & Research subindustry, Pacific Edge's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacific Edge Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pacific Edge's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Pacific Edge's Cyclically Adjusted PS Ratio falls into.
Pacific Edge Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Pacific Edge's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 12.00 mean?
Pacific Edge (ASX:PEB) has a Cyclically Adjusted PS Ratio of 12.00 as of Jul. 15, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pacific Edge and its competitors. This is 62% below median its historical median of 31.54. Over the past decade, Pacific Edge's Cyclically Adjusted PS Ratio has ranged from 2.90 to 156.00. According to the industry distribution chart, Pacific Edge ranks #125 out of 136 companies in the Medical Diagnostics & Research industry, placing it in the top 91.9%.
Is Pacific Edge's Cyclically Adjusted PS Ratio too high?
Pacific Edge's current Cyclically Adjusted PS Ratio of 12.00 is 62% below median its 10-year median of 31.54. Over the past 10 years, this metric has ranged from a low of 2.90 to a high of 156.00. The Medical Diagnostics & Research industry median Cyclically Adjusted PS Ratio is 2.00. Pacific Edge's value of 12.00 is 500% above this industry median. Based on the distribution chart, Pacific Edge ranks #125 out of 136 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Pacific Edge has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pacific Edge's Cyclically Adjusted PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pacific Edge ranks #125 out of 136 companies for Cyclically Adjusted PS Ratio. This places Pacific Edge in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 2.00. Pacific Edge's value of 12.00 is 500% above this benchmark. Historically, Pacific Edge's own Cyclically Adjusted PS Ratio has ranged from 2.90 to 156.00 over the past decade. While the company's 10-year median is 31.54 vs. the industry median of 2.00, Pacific Edge has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Diagnostics & Research company?
The median Cyclically Adjusted PS Ratio among Medical Diagnostics & Research companies is 2.00, based on 136 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacific Edge's current Cyclically Adjusted PS Ratio of 12.00 is 500% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pacific Edge and its competitors. For the Medical Diagnostics & Research industry, the median Cyclically Adjusted PS Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacific Edge's current Cyclically Adjusted PS Ratio is 12.00, which is 62% below median its own 10-year median of 31.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Edge stock overvalued right now?
Based on GuruFocus' analysis, Pacific Edge (ASX:PEB) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.05, compared to a current price of A$0.24 — trading 380% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 12.00, which is 62% below median its 10-year median of 31.54 and 500% above the Medical Diagnostics & Research industry median of 2.00. Pacific Edge's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Pacific Edge (ASX:PEB), the current Cyclically Adjusted PS Ratio is 12.00 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacific Edge (ASX:PEB) Overvalued in 2026?
Based on GuruFocus' analysis, Pacific Edge stock appears to be overvalued.
The current stock price of A$0.24 is trading 380% above its estimated GF Value™ of A$0.05.
GuruFocus considers Pacific Edge to be Significantly Overvalued.
Key valuation signals for ASX:PEB:
Cyclically Adjusted PS Ratio: 12.00 (62% below median its 10-year median of 31.54)
GF Value™: A$0.05 vs. price of A$0.24 (380% above fair value)
Industry Position: 500% above the Medical Diagnostics & Research median (#125 of 136)
No single metric tells the full story. See the ASX:PEB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacific Edge Ltd is a New Zealand-based company involved in researching, developing, and commercialising new diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. It operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses internationally; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, which generates maximum revenue, New Zealand, and the Rest of the World.
40GF Score
Get the complete analysis for ASX:PEB
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PEB has been successfully added to your 
